Immunological risk factors for infection after immunosuppressive and biologic therapies

References

• Fishman JA, Issa NC. Infection in organ transplantation: risk factors and evolving patterns of infection. Infect. Dis. Clin. North Am.24(2), 273–283 (2010).
   PubMedGoogle Scholar
• Carbone J, Lanio N, Gallego A, Sarmiento E. Immune monitoring to predict the development of infections after immunosuppression for solid organ transplantation and autoimmune diseases. Curr. Drug Saf.3(2), 91–99 (2008).
   PubMedGoogle Scholar
• Wehr C, Kivioja T, Schmitt C et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood111(1), 77–85 (2008).
   PubMed Web of Science ®Google Scholar
• Coetzee LM, Tay SS, Lawrie D, Janossy G, Glencross DK. From research tool to routine test: CD38 monitoring in HIV patients. Cytometry B Clin. Cytom.76(6), 375–384 (2009).
   PubMedGoogle Scholar
• Butterfield LH, Disis ML, Fox BA et al. A systematic approach to biomarker discovery; preamble to “the iSBTc-FDA taskforce on immunotherapy biomarkers”. J. Transl. Med.6, 81 (2008).
   PubMed Web of Science ®Google Scholar
• Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin. Arthritis Rheum.39(5), 327–346 (2010).
   PubMed Web of Science ®Google Scholar
• Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs70(11), 1445–1476 (2010).
   PubMed Web of Science ®Google Scholar
• Nam JL, Winthrop KL, van Vollenhoven RF et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann. Rheum. Dis.69(6), 976–986 (2010).
   PubMed Web of Science ®Google Scholar
• Cooper N, Arnold DM. The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br. J. Haematol.149(1), 3–13 (2010).
   PubMed Web of Science ®Google Scholar
• Gottenberg J, Ravaud P, Bardin T et al. Risk factors of severe infections in patients with rheumatoid arthritis treated with rituximab in the AutoImmunity and Rituximab (AIR) registry. Arthritis Rheum.62(9), 2625–2632 (2010).
   PubMed Web of Science ®Google Scholar
• Keystone E, Fleischmann R, Emery P et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum.56(12), 3896–3908 (2007).
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Emery P, Bingham CO 3rd et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J. Rheumatol.37(3), 558–567 (2010).
   PubMed Web of Science ®Google Scholar
• Nishio M, Fujimoto K, Yamamoto S et al. Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Eur. J. Haematol.77(3), 226–232 (2006).
   PubMed Web of Science ®Google Scholar
• Rehnberg M, Amu S, Tarkowski A, Bokarewa MI, Brisslert M. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res. Ther.11(4), R123 (2009).
   PubMed Web of Science ®Google Scholar
• Muhammad K, Roll P, Einsele H, Dörner T, Tony HP. Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment. Arthritis Rheum.60(8), 2284–2293 (2009).
   PubMedGoogle Scholar
• Nishio M, Fujimoto K, Yamamoto S et al. Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Br. J. Haematol.137(4), 349–354 (2007).
   PubMed Web of Science ®Google Scholar
• Sidner RA, Book BK, Agarwal A, Bearden CM, Vieira CA, Pescovitz MD. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum. Antibodies13(3), 55–62 (2004).
   PubMedGoogle Scholar
• Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum.56, 3909–3918 (2007).
   PubMed Web of Science ®Google Scholar
• Nishio M, Endo T, Fujimoto K et al. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin’s lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation. Eur. J. Haematol.82(2), 143–147 (2009).
   PubMedGoogle Scholar
• Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med.358, 676–688 (2008).
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Calabresi PA, Arnold D et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, Phase I trial. Ann. Neurol.63, 395–400 (2008).
   PubMed Web of Science ®Google Scholar
• Levi ME, Quan D, Ho JT, Kleinschmidt-Demasters BK, Tyler KL, Grazia TJ. Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipients. Clin. Transplant.24(2), 223–228 (2010).
   PubMedGoogle Scholar
• Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann. Oncol.17(9), 1424–1427 (2006).
   PubMed Web of Science ®Google Scholar
• Diwakar L, Gorrie S, Richter A et al. Does rituximab aggravate pre-existing hypogammaglobulinaemia? J. Clin. Pathol.63(3), 275–277 (2010).
   PubMedGoogle Scholar
• Yamani MH, Avery RK, Mawhorter SD et al. Hypogammaglobulinemia following cardiac transplantation: a link between rejection and infection. J. Heart Lung Transplant.20(4), 425–430 (2001).
   PubMedGoogle Scholar
• Sarmiento E, Rodríguez-Molina J, Muñoz P et al. Decreased levels of serum immunoglobulins as a risk factor for infection after heart transplantation. Transplant. Proc.37, 4046–4069 (2005).
   PubMedGoogle Scholar
• Sarmiento E, Rodriguez-Molina JJ, Fernandez-Yañez J et al. IgG monitoring to identify the risk for development of infection in heart transplant recipients. Transpl. Infect. Dis.8, 49–53 (2006).
   PubMedGoogle Scholar
• Muñoz P, Giannella M, Alcalá L et al. Clostridium difficile-associated diarrhea in heart transplant recipients: is hypogammaglobulinemia the answer? J. Heart Lung Transplant.26, 907–914 (2007).
   PubMed Web of Science ®Google Scholar
• Goldfarb NS, Avery RK, Goormastic M et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation71, 242–246 (2001).
   PubMed Web of Science ®Google Scholar
• Kawut SM, Shah L, Wilt JS et al. Risk factors and outcomes of hypogammaglobulinemia after lung transplantation. Transplantation79, 1723–1726 (2005).
   PubMedGoogle Scholar
• Robertson J, Elidemir O, Saz EU et al. Hypogammaglobulinemia: incidence, risk factors, and outcomes following pediatric lung transplantation. Pediatr. Transplant.13(6), 754–759 (2009).
   PubMedGoogle Scholar
• Carbone J, Micheloud D, Salcedo M et al. Humoral and cellular immune monitoring might be useful to identify liver transplant recipients at risk for development of infection. Transpl. Infect. Dis.10, 396–402 (2008).
   PubMed Web of Science ®Google Scholar
• Cuervas-Mons V, Millan I, Gavaler JS, Starzl TE, Van Thiel DH. Prognostic value of preoperatively obtained clinical and laboratory data in predicting survival following orthotopic liver transplantation. Hepatology6, 922–927 (1986).
   PubMed Web of Science ®Google Scholar
• Schmilovitz-Weiss H, Cohen M, Pappo O et al. Serum globulin levels in predicting the extent of hepatic fibrosis in patients with recurrent post-transplant hepatitis C infection. Clin. Transplant.21, 391–397 (2007).
   PubMed Web of Science ®Google Scholar
• Doron S, Ruthazer R, Werner BG, Rabson A, Snydman DR. Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes. Transplantation81, 697–703 (2006).
   PubMedGoogle Scholar
• González-Quintela A, López-Ben S, Pérez LF et al. Time-course changes of serum immunoglobulins (IgA, IgG, IgM) after liver transplantation for alcoholic cirrhosis. Transpl. Immunol.11(1), 73–77 (2003).
   PubMedGoogle Scholar
• Van Thiel DH, Finkel R, Friedlander L, Gavaler JS, Wright HI, Gordon R. The association of IgA deficiency but not IgG or IgM deficiency with a reduced patient and graft survival following liver transplantation. Transplantation54(2), 269–273 (1992).
   PubMedGoogle Scholar
• Pollock CA, Mahony JF, Ibels LS et al. Immunoglobulin abnormalities in renal transplant recipients. Transplantation47(6), 952–956 (1989).
   PubMed Web of Science ®Google Scholar
• Broeders EN, Wissing KM, Hazzan M et al. Evolution of immunoglobulin and mannose binding protein levels after renal transplantation: association with infectious complications. Transpl. Int.21(1), 57–64 (2008).
   PubMed Web of Science ®Google Scholar
• Boddana P, Webb LH, Unsworth J, Brealey M, Bingham C, Harper SJ. Hypogammaglobulinemia and bronchiectasis in mycophenolate mofetil treated renal transplant recipients: an emerging clinical phenomenon? Clin. Transplant DOI: 10.1111/j.1399–0012.2010.01255.x. (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Mawhorter S, Yamani MH. Hypogammaglobulinemia and infection risk in solid organ transplant recipients. Curr. Opin. Organ Transplant.13(6), 581–585 (2008).
   PubMed Web of Science ®Google Scholar
• Hosseini-Moghaddam SM, Husain S. Fungi and molds following lung transplantation. Semin. Respir. Crit. Care Med.31(2), 222–233 (2010).
   PubMedGoogle Scholar
• Poonyagariyagorn HK, Gershman A, Avery R et al. Challenges in the diagnosis and management of Nocardia infections in lung transplant recipients. Transpl. Infect. Dis.10(6), 403–408 (2008).
   PubMedGoogle Scholar
• Sarmiento E, Rodriguez-Molina J, Lanio N et al. Risk factors of hypogammaglobulinemia in risk factors of hypogammaglobulinemia in heart transplantation. Presented at: American Transplant Congress. 31 May–4 June, Toronto, ON, Canada (2008).
   Google Scholar
• Yamani MH, Avery R, Mawhorter S et al. Hypogammaglobulinemia after heart transplantation: impact of pre-emptive use of immunoglobulin replacement (CytoGam) on infection and rejection outcomes. Transpl. Infect. Dis.3(Suppl. 2), 40–43 (2001).
   PubMedGoogle Scholar
• Carbone J, Sarmiento E, Palomo J et al. The potential impact of substitutive therapy with intravenous immunoglobulin on the outcome of heart transplant recipients with infections. Transplant. Proc.39(7), 2385–2388 (2007).
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation89(7), 779–795 (2010).
   PubMed Web of Science ®Google Scholar
• Walker S, Fazou C, Crough T et al. Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV. Transpl. Infect. Dis.9(2), 165–170 (2007).
   PubMed Web of Science ®Google Scholar
• Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am. J. Transplant.8(8), 1749–1754 (2008).
   PubMed Web of Science ®Google Scholar
• Mattes FM, Vargas A, Kopycinski J et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am. J. Transplant.8(5), 990–999 (2008).
   PubMedGoogle Scholar
• Gerna G, Lilleri D, Fornara C et al. Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am. J. Transplant.6, 2356–2364 (2006).
   PubMed Web of Science ®Google Scholar
• Lilleri D, Zelini P, Fornara C, Comolli G, Gerna G. Inconsistent responses of cytomegalovirus-specific T cells to pp65 and IE-1 versus infected dendritic cells in organ transplant recipients. Am. J. Transplant.7, 1997–2005 (2007).
   PubMedGoogle Scholar
• Shlobin OA, West EE, Lechtzin N et al. Persistent cytomegalovirus-specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J. Immunol.176, 2625–2634 (2006).
   PubMedGoogle Scholar
• La Rosa C, Limaye AP, Krishnan A et al. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J. Infect. Dis.195, 633–644 (2007).
   PubMed Web of Science ®Google Scholar
• Benz C, Utermohlen O, Wulf A et al. Activated virus-specific T cells are early indicators of anti-CMV immune reactions in liver transplant patients. Gastroenterology122, 1201–1215 (2002).
   PubMedGoogle Scholar
• Sester U, Presser D, Dirks J, Gärtner BC, Köhler H, Sester M. PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy. Am. J. Transplant.8(7), 1486–1497 (2008).
   PubMedGoogle Scholar
• Sarmiento E, Lanio N, Gallego A et al. Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation. Int. Immunopharmacol.9(6), 649–652 (2009).
   PubMed Web of Science ®Google Scholar
• Manuel O, Pascual M, Trendelenburg M, Meylan PR. Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation83, 359–362 (2007).
   PubMedGoogle Scholar
• Cervera C, Lozano F, Saval N et al. The influence of innate immunity gene receptors polymorphisms in renal transplant infections. Transplantation83, 1493–1500 (2007).
   PubMedGoogle Scholar
• Kijpittayarit S, Eid AJ, Brown RA, Paya CV, Razonable RR. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation. Clin. Infect. Dis.44, 1315–1320 (2007).
   PubMedGoogle Scholar
• Helanterä I, Koskinen P. Association of immune cell function assay with protocol biopsy findings and viral infections in well matched kidney transplant recipients. Clin. Nephrol.74(2), 123–31 (2010).
   PubMedGoogle Scholar
• Zeevi A, Husain S, Spichty KJ et al. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am. J. Transplant.7(2), 471–475 (2007).
   PubMedGoogle Scholar
• Crough T, Fazou C, Weiss J et al. Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8(+) T-cell response. J. Virol.81(20), 11538–11542 (2007).
   PubMedGoogle Scholar
• Wynn KK, Crought T, Campbell S et al. Narrowing of T-cell receptor β variable repertoire during symptomatic herpesvirus infection in transplant patients. Immunol. Cell. Biol.88(2), 125–135 (2010).
   PubMedGoogle Scholar
• Sarmiento E, Lanio N, Gallego A et al. Simultaneous immune monitoring of specific anti-cytomegalovirus humoral and cellular responses in heart transplant patients. Presented at: 1st Congress of the Spanish Transplantation Society. Seville, Spain, 2–5 June 2010.
   Google Scholar
• Bunk S, Schaffert H, Schmid B et al. Chlamydia pneumoniae-induced memory CD4+ T-cell activation in human peripheral blood correlates with distinct antibody response patterns. Clin. Vaccine Immunol.17(5), 705–712 (2010).
   PubMedGoogle Scholar
• Mui TS, Kapp M, Einsele H, Grigoleit GU. T-cell therapy for cytomegalovirus infection. Curr. Opin. Organ Transplant. DOI: 10.1097/MOT.0b013e32834016b9 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Brestrich G, Zwinger S, Fischer A et al. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am. J. Transplant.9(7), 1679–1684 (2009).
   PubMed Web of Science ®Google Scholar
• Haddad F, Deuse T, Pham M et al. Changing trends in infectious disease in heart transplantation. J. Heart Lung Transplant.29(3), 306–315 (2010).
   PubMedGoogle Scholar
• Koetz K, Bryl E, Spickschen K, O’Fallon WM, Goronzy JJ, Weyand CM. T cell homeostasis in patients with rheumatoid arthritis. Proc. Natl Acad. Sci. USA97(16), 9203–9208 (2000).
   PubMed Web of Science ®Google Scholar
• Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford)50(1), 222–229 (2011).
   PubMed Web of Science ®Google Scholar